Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: A systematic review and meta-analysis
Expert Opin Drug Saf 2024;23:1–9 doi: 10.1080/14740338.2024.2343017 Epub ahead of print
Bimekizumab was superior to placebo in achieving ACR, MDA, and PASI outcomes and had an acceptable safety profile. This meta-analysis also showed that 160mg and 320mg doses of bimekizumab were both superior to placebo in achieving these outcome measures.